With a deal and a debut, targeted oligo delivery gets a boost from ADCs

How antibody-oligonucleotide conjugates could bring out the best of both modalities

The marriage of antibody-drug conjugates and oligonucleotides won two votes of confidence last month with a deal between Lilly and Avidity, and the debut of Atlas-backed Dyne Therapeutics. The approach promises delivery of oligos to tissues outside the liver, taking advantage of advances in both ADCs and oligo therapeutics, but faces design challenges to ensure the payload reaches intracellular targets at the right time and in the right dose.

On April 22, Eli Lilly and Co. obtained global rights to antibody-oligo conjugate technology from Avidity Biosciences LLC to develop therapies for immunology indications. Lilly paid $20 million up front and made a $15 million investment in Avidity, which is also eligible for up to $405 million in milestones per target. The identity and number of targets are undisclosed.

Prior to the deal, Avidity had raised a total of $30 million in venture financing since launching in 2014.

On April 3, Dyne Therapeutics Inc., which was founded and incubated by Atlas Venture, debuted

Read the full 1612 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE